Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus.

Expansion of extracellular matrix with fibrosis occurs in many tissues as part of the end-organ complications in diabetes, and advanced glycosylation end products (AGE) are implicated as one causative factor in diabetic tissue fibrosis. Connective tissue growth factor (CTGF), also known as insulin-like growth factor-binding protein-related protein-2 (IGFBP-rP2), is a potent inducer of extracellular matrix synthesis and angiogenesis and is increased in tissues from rodent models of diabetes. The aim of this study was to determine whether CTGF is up-regulated by AGE in vitro and to explore the cellular mechanisms involved. AGE treatment of primary cultures of nonfetal human dermal fibroblasts in confluent monolayer increased CTGF steady state messenger RNA (mRNA) levels in a time- and dose-dependent manner. In contrast, mRNAs for other IGFBP superfamily members, IGFBP-rP1 (mac 25) and IGFBP-3, were not up-regulated by AGE. The effect of the AGE BSA reagent on CTGF mRNA was due to nonenzymatic glycosylation of BSA and, using neutralizing antisera to AGE and to the receptor for AGE, termed RAGE, was seen to be due to late products of nonenzymatic glycosylation and was partly mediated by RAGE. Reactive oxygen species as well as endogenous transforming growth factor-beta1 could not explain the AGE effect on CTGF mRNA. AGE also increased CTGF protein in the conditioned medium and cell-associated CTGF. Thus, AGE up-regulates the profibrotic and proangiogenic protein CTGF (IGFBP-rP2), a finding that may have significance in the development of diabetic complications.

[1]  Y. Kaneda,et al.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.

[2]  M. Brownlee,et al.  Negative consequences of glycation. , 2000, Metabolism: clinical and experimental.

[3]  R. Bucala,et al.  Structure of a synthetic glucose derived advanced glycation end product that is immunologically cross-reactive with its naturally occurring counterparts. , 2000, Bioconjugate chemistry.

[4]  J. Yee,et al.  Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. , 2000, Journal of the American Society of Nephrology : JASN.

[5]  T. Kislinger,et al.  N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.

[6]  Gary R. Grotendorst,et al.  Connective tissue growth factor mediates transforming growth factor b-induced collagen synthesis : down-regulation by cAMP , 1999 .

[7]  H. Friess,et al.  Connective tissue growth factor is a regulator for fibrosis in human chronic pancreatitis. , 1999, Annals of surgery.

[8]  R. G. Paul,et al.  The effect of advanced glycation end-product formation upon cell-matrix interactions. , 1999, The international journal of biochemistry & cell biology.

[9]  G. King,et al.  Theoretical mechanisms by which hyperglycemia and insulin resistance could cause cardiovascular diseases in diabetes. , 1999, Diabetes care.

[10]  L. Lau,et al.  Fisp12/Mouse Connective Tissue Growth Factor Mediates Endothelial Cell Adhesion and Migration through Integrin αvβ3, Promotes Endothelial Cell Survival, and Induces Angiogenesis In Vivo , 1999, Molecular and Cellular Biology.

[11]  F. Cuccurullo,et al.  Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. , 1999, The Journal of pediatrics.

[12]  A. Schmidt,et al.  Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. , 1999, Circulation research.

[13]  F. Martin,et al.  Suppression Subtractive Hybridization Identifies High Glucose Levels as a Stimulus for Expression of Connective Tissue Growth Factor and Other Genes in Human Mesangial Cells* , 1999, The Journal of Biological Chemistry.

[14]  Paul J Thornalley.  Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. , 1998, Cellular and molecular biology.

[15]  A. Schmidt,et al.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.

[16]  Gary R. Grotendorst,et al.  Connective tissue growth factor: a novel regulator of mucosal repair and fibrosis in inflammatory bowel disease? , 1998, The international journal of biochemistry & cell biology.

[17]  M. Brauchle,et al.  Dexamethasone Is a Novel Potent Inducer of Connective Tissue Growth Factor Expression , 1998, The Journal of Biological Chemistry.

[18]  E. Wilson,et al.  Identification of glycosylated 38-kDa connective tissue growth factor (IGFBP-related protein 2) and proteolytic fragments in human biological fluids, and up-regulation of IGFBP-rP2 expression by TGF-beta in Hs578T human breast cancer cells. , 1998, The Journal of clinical endocrinology and metabolism.

[19]  A. Schmidt,et al.  Enhanced interaction of advanced glycation end products with their cellular receptor RAGE: implications for the pathogenesis of accelerated periodontal disease in diabetes. , 1998, Annals of periodontology.

[20]  M. Takigawa,et al.  Inhibition of endogenous expression of connective tissue growth factor by its antisense oligonucleotide and antisense RNA suppresses proliferation and migration of vascular endothelial cells. , 1998, Journal of biochemistry.

[21]  R. O. Stuart,et al.  Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. , 1998, Kidney international.

[22]  R. Bende,et al.  Expression of connective tissue growth factor in human renal fibrosis. , 1998, Kidney international.

[23]  R. Bucala,et al.  Advanced glycation end products increase retinal vascular endothelial growth factor expression. , 1998, The Journal of clinical investigation.

[24]  R. Ziegler,et al.  AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. , 1998, Cardiovascular research.

[25]  P. A. Harding,et al.  Characterization of cell-associated and soluble forms of connective tissue growth factor (CTGF) produced by fibroblast cells in vitro. , 1998, Growth factors.

[26]  S. Mohan,et al.  Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily. , 1998, Endocrinology.

[27]  N. Nakamura,et al.  Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells. , 1997, Biochemical and biophysical research communications.

[28]  E. Wilson,et al.  Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): characterization of connective tissue growth factor as a member of the IGFBP superfamily. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[29]  K. Swisshelm,et al.  Developmental regulation of Mac25/insulin-like growth factor-binding protein-7 expression in skeletal myogenesis. , 1997, Experimental cell research.

[30]  G. Romeo,et al.  Upregulation of Mesangial Growth Factor and Extracellular Matrix Synthesis by Advanced Glycation End Products Via a Receptor-Mediated Mechanism , 1997, Diabetes.

[31]  T. Luther,et al.  Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. , 1997, Circulation.

[32]  Gary R. Grotendorst.  Connective tissue growth factor: a mediator of TGF-β action on fibroblasts , 1997 .

[33]  A. Schmidt,et al.  Activation of the Receptor for Advanced Glycation End Products Triggers a p21 ras -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress* , 1997, The Journal of Biological Chemistry.

[34]  R. Bucala,et al.  Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Hiroshi Yamamoto,et al.  Advanced Glycation End Products-driven Angiogenesis in Vitro , 1997, The Journal of Biological Chemistry.

[36]  A. Schmidt,et al.  What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose , 1997, European journal of clinical investigation.

[37]  W. März,et al.  Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. , 1997, Circulation.

[38]  P. Riederer,et al.  Determination of Advanced Glycation End Products in Serum by Fluorescence Spectroscopy and Competitive ELISA , 1997, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[39]  Gary R. Grotendorst,et al.  Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. , 1996, The Journal of investigative dermatology.

[40]  Gary R. Grotendorst,et al.  A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[41]  G. Striker,et al.  Administration of AGEs in vivo induces extracellular matrix gene expression. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[42]  Gary R. Grotendorst,et al.  Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. , 1995, The Journal of investigative dermatology.

[43]  L. L. Moore,et al.  Formation of Immunochemical Advanced Glycosylation End Products Precedes and Correlates With Early Manifestations of Renal and Retinal Disease in Diabetes , 1995, Diabetes.

[44]  M. Cybulsky,et al.  Advanced Glycation Endproducts Promote Adhesion Molecule (VCAM-1, ICAM-1) Expression and Atheroma Formation in Normal Rabbits , 1995, Molecular medicine.

[45]  A. Schmidt,et al.  Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[46]  G. Striker,et al.  Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Gary R. Grotendorst,et al.  Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. , 1993, Molecular biology of the cell.

[48]  A. Huntley.  Cutaneous manifestations of diabetes mellitus. , 1982, Diabetes/metabolism reviews.

[49]  H. Vlassara,et al.  Receptor-Mediated Interactions of Advanced Glycosylation End Products With Cellular Components Within Diabetic Tissues , 1992, Diabetes.

[50]  V. Monnier,et al.  Pentosidine Formation in Skin Correlates With Severity of Complications in Individuals With Long-Standing IDDM , 1992, Diabetes.

[51]  R. Baxter,et al.  Insulin-like growth factor-I (IGF-I) and transforming growth factor-beta 1 release IGF-binding protein-3 from human fibroblasts by different mechanisms. , 1992, Endocrinology.

[52]  R. Bucala,et al.  Immunochemical detection of advanced glycosylation end products in vivo. , 1992, The Journal of biological chemistry.

[53]  C. Bombardier,et al.  Pathologic features of diabetic thick skin. , 1987, Journal of the American Academy of Dermatology.

[54]  A. Cerami,et al.  Nonenzymatic glycosylation: role in the pathogenesis of diabetic complications. , 1986, Clinical chemistry.

[55]  J. Seibold.  Digital sclerosis in children with insulin-dependent diabetes mellitus. , 1982, Arthritis and rheumatism.